# US 6,727,252 B1 · Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,252 B1
- Document ID: US6727252B1
- Status: Granted
- Kind: B1
- Application number: 09/688,199
- Filed: 2000-10-16
- Granted: 2004-04-27
- Earliest claimed: 1997-10-06
- Assignees: Zentaris AG
- Inventors: Gerald McMahon; Heinz Weinberger; Bernhard Kutscher; Harald App
- Web page: https://patentgrep.com/patent/US6727252B1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with 5-azaquinoxaline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to 5-azaquinoxaline compounds and pharmaceutical compositions comprising these compounds.

## Claims

### Claim 1

A method of modulating the function of a serine/threonine protein kinase with a pyrido[2,3-b]pyrazine-based compound, comprising contacting cells expressing the serine/threonine protein kinase with the compound, wherein the pyrido[2,3-b]pyrazine-based compound has the formula set forth in structure I:
wherein
(a) R1, R2, R3, R4 and R6 are independently selected from the group consisting of
(i) hydrogen;
(ii) saturated alkyl or unsaturated alkyl, optionally substituted with a five-membered aryl, six-membered aryl, five-membered heteroaryl, or six-membered heteroaryl ring moiety, wherein the ring moiety is optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl halogen, trihalomethyl, carboxylate, nitro, and ester moieties;
(iii) an amine of formula —NX2X3, wherein X2 and X3 are independently selected from the group consisting of hydrogen, saturated alkyl, unsaturated alkyl, five-membered aryl, six-membered aryl, five-membered heteroaryl, and six-membered heteroaryl moieties;
(iv) halogen or trihalomethyl;
(v) a ketone of formula —CO—X4, wherein X4 is selected from the group consisting of hydrogen, alkyl, five-membered aryl, and five-membered heteroaryl moieties;
(vi) a carboxylic acid of formula —(X5)n—COOH or an ester of formula —(X6)n—COO—X7, wherein X5, X6 and X7 are independently selected from the group consisting of alkyl, five-membered aryl, six-membered aryl, five-membered heteroaryl, and six-membered heteroaryl moieties, and wherein n is 0 or 1;
(vii) an alcohol of formula (X8)n—OH or an alkoxy moiety of formula —(X8)n—O—X9, wherein X8 and X9 are independently selected from the group consisting of hydrogen, saturated alkyl, unsaturated alkyl, five-membered aryl, six-membered aryl, five-membered heteroaryl, and six-membered heteroaryl ring moieties, wherein the ring is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester, and wherein n is 0 or 1;
(viii) an amide of formula —NHCOX10, wherein X10 is selected from the group consisting of alkyl, hydroxyl, five-membered aryl, six-membered aryl, five-membered heteroaryl, and six-membered heteroaryl moieties, wherein the ring is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester;
(ix) —SO2NX11X12, where X11 and X12 are independently selected from the group consisting of hydrogen, alkyl, five-membered aryl, six-membered aryl, five-membered heteroaryl, and six-membered heteroaryl moieties;
(x) a five-membered aryl, six-membered aryl, five-membered heteroaryl, or six-membered heteroaryl moiety optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester moieties;
(xi) an aldehyde of formula —CO—H; and
(xii) a sulfone of formula —SO2—X13, where X13 is selected from the group consisting of saturated alkyl, unsaturated alkyl, five-membered aryl, six-membered aryl, five-membered heteroaryl, and six-membered heteroaryl moieties; and
(b) X1 is selected from the group consisting of NH, S and O.

### Claim 2 (depends on 1)

The method of claim 1, wherein said R1, R2, R3, R4, and R6 are independently selected from the group consisting of:
(i) hydrogen;
(ii) saturated alkyl or unsaturated alkyl, optionally substituted with a five-membered aryl, six-membered aryl, five-membered heteroaryl, or six-membered heteroaryl ring moiety, wherein the ring moiety is optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl halogen, trihalomethyl, carboxylate, nitro, and ester moieties;
(iii) a five-membered aryl, six-membered aryl, five-membered heteroaryl, or six-membered heteroaryl moiety optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester moieties.

### Claim 3 (depends on 2)

The method of claim 2, wherein said R1 and R2 are independently selected from the group consisting of:
(i) hydrogen; and
(ii) phenyl optionally substituted with a substituent selected from the group consisting of alkyl, halogen, trihalomethyl, nitro, carboxylate, hydroxy, and alkoxy moieties.

### Claim 4 (depends on 3)

The method of claim 3, wherein said X1 is NH or O.

### Claim 5 (depends on 4)

The method of claim 4, wherein the R6 and X1 substituents taken together form a moiety selected from the group consisting of methoxy, benzylamino, 4-fluorobenzylamino, 2-carboxybenzylamino, 3-carboxybenzylamino, 4-carboxybenzylamino, 2-nitrobenzylamino, 3-nitrobenzylamino, 4-nitrobenzylamino, 2-methylbenzylamino, 3-methylbenzylamino, 4-methylbenzylamino, 2-chlorobenzylamino, 3-chlorobenzylamino, 4-chlorobenzylamino, 2-fluorobenzylamino, 3-fluorobenzylamino, 4-fluorobenzylamino, 2-(trifluoromethyl)benzylamino, 3-(trifluoromethyl)benzylamino, 4-(trifluoromethyl)benzylamino, phenethyl-1-amino, phenylamino, 2-carboxyphenylamino, 3-carboxyphenylamino, 4-carboxyphenylamino, 2-nitrophenylamino, 3-nitrophenylamino, 4-nitrophenylamino, 2-methylphenylamino, 3-methylphenylamino, 4-methylphenylamino, 2-chlorophenylamino, 3-chlorophenylamino, 4-chlorophenylamino, 2-fluorophenylamino, 3-fluorophenylamino, 4-fluorophenylamino, 2-(trifluoromethyl)phenylamino, 3-(trifluoromethyl)phenylamino, 4-(trifluoromethyl)phenylamino, pyrid-2-amino, pyrid-3-amino, pyrid4-amino, and pyrid-2-methylamino.

### Claim 6 (depends on 2)

The method of claim 2, wherein the pyrido[2,3-b]pyrazine-based compound comprises an R2 that is a methyl group and an R1 that is a phenyl group optionally substituted with a substituent selected from the group consisting of alkyl, halogen, trihaomethyl, nitro, carboxylate, hydroxy, and alkoxy.
